This study is testing a new medicine called **INBRX-109** for people with certain types of cancer, including a rare one called **sarcoma**. A sarcoma is a tumor that starts in bones or soft tissues. The study is open-label, meaning everyone knows what treatment is being given, and non-randomized, so there's no lottery to decide who gets the treatment. It's a **Phase 1** trial, the first time this medicine is being tested in humans.

**Eligibility:** People aged 12 to 84 with specific cancers can join if they meet certain health conditions. The study checks if the cancer can be measured and if the participant is healthy enough, including having good blood and organ function.

**Key Points:**

• The study involves taking INBRX-109 and possibly other treatments.
• Participants should not have had certain other cancer treatments recently.
• Participants must provide tissue samples for analysis.

**Risks:** Side effects could include reactions to the drug or existing health conditions worsening. It's important to discuss with your doctor if joining is right for you.